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PInsulin as an Anti-Inflammatory
and Antiatherogenic Modulator
Paresh Dandona, MD, PHD,* Ajay Chaudhuri, MD,* Husam Ghanim, PHD,* Priya Mohanty, MD†
Buffalo, New York
Data demonstrate the anti-inflammatory effects of insulin and proinflammatory effects of glucose. These data
provide a mechanistic justification for the benefits of maintaining euglycemia with insulin infusions in hospital-
ized patients. Regimens that infuse fixed doses of insulin with high rates of glucose are usually associated with
hyperglycemia, which may neutralize the beneficial effects of insulin. Therefore, we propose that such regimens
should be avoided and instead replaced by insulin infusions that normalize and maintain blood glucose at a rea-
sonably low level and ensure that plasma insulin is maintained at levels high enough to provide clinically rele-
vant anti-inflammatory and cardioprotective effects. Trials to test this hypothesis are in progress. (J Am Coll
Cardiol 2009;53:S14–20) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.038i
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pince its discovery in 1921, insulin has been considered a key
etabolic hormone with profound effects on glucose and lipid
etabolism as well as cardiovascular function, as reviewed
lsewhere in this supplement. Additionally, over the past
ecade, data have emerged on the different effects of insulin
nd hyperglycemia on inflammatory processes. This article will
ummarize these data and discuss their implications for man-
gement of patients with acute myocardial infarction (AMI).
roinflammatory Effect of Glucose
ur group has shown that acute challenge with 75-g
lucose given orally causes an increase in superoxide radical
eneration by polymorphonuclear leukocytes and mononu-
lear cells and increased expression of p47
phox, an essential
omponent of the enzyme nicotinamide adenine dinucle-
tide phosphate hydrogen oxidase, which converts molecu-
ar O2 to superoxide radical (1). Downstream consequences
nclude activation of redox-sensitive proinflammatory tran-
cription factors such as nuclear factor-kappa B (NF-kB),
ctivator protein-1, early growth response-1, and hypoxia
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ccepted October 7, 2008.nducible factor-alpha, with concomitant increases in ex-
ression of matrix metalloproteinases and tissue factor by
ononuclear cells (2,3). Likewise, Esposito et al. (4) dem-
nstrated that the induction of steady-state hyperglycemia
ith intravenous glucose infusion with concomitant inhibi-
ion of endogenous insulin secretion with somatostatin led
o an increase in plasma tumor necrosis factor-alpha and
nterleukin-6 concentrations. Finally, Monnier et al. (5)
orrelated acute glucose excursions with induction of oxi-
ative stress in subjects with type 2 diabetes mellitus.
Hyperglycemia-related oxidative stress reduces the bio-
vailability of nitric oxide (NO) because superoxide radical
ombines with NO to form peroxynitrite. NO causes
asodilation and has inhibitory effects on platelet adhesion
nd aggregation (6,7). In addition, tissue factor is an
ctivator of the extrinsic pathway of coagulation and is
nvolved in the conversion of prothrombin to thrombin (3).
hrombin is a potent platelet aggregator and induces the
onversion of fibrinogen to fibrin. Thrombin also triggers
roinflammatory pathways, while platelets release CD40
igand, a powerful inflammatory trigger (8). Thus, inflam-
ation caused by elevated glucose concentrations induces a
asoconstrictive, prothrombotic state and thrombosis begets
urther inflammation. Moreover, elevated plasma levels of
he inflammatory marker C-reactive protein (CRP) are
ssociated with increased incidence of arrhythmias (9).
hese mechanisms may contribute to the adverse outcomes
ssociated with hyperglycemia in patients with acute coro-
ary syndromes (ACS) (10–13). Hyperglycemia is also
ssociated with a reduction in spontaneous reperfusion,
educed rate of Thrombolysis In Myocardial Infarction
TIMI) flow grade 3, and a higher rate of no reflow after
rimary percutaneous coronary intervention in AMI
14,15). Moreover, chronic hyperglycemia and high hemo-
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oronary intervention success rate in people with diabetes (16).
eactive Oxygen Species Suppression
nd the Anti-Inflammatory Effects of Insulin
nsulin induces expression of endothelial NO synthase
hrough the activation of phosphatidylinositol kinase (PI3)
nd AkT kinase (protein kinase B), an insulin signaling
echanism similar to that which mediates the uptake of
lucose through the glucose transporter (17). In turn,
ndothelial NO synthase generates NO. Human studies
ave demonstrated that insulin increases blood flow at the
rterial, venous, and microcirculatory levels (18), effects that
re NO-dependent. Insulin also inhibits platelet aggrega-
ion via a NO-dependent effect (7).
In vitro studies showed that insulin suppressed intracel-
ular adhesion molecule-1, monocyte chemoattractant
rotein-1 expression, and NF-kB binding in human aortic
ndothelial cells (19). In obese subjects, who typically are
nsulin resistant and have chronic inflammation, we further
howed that low-dose insulin infusion (2 U/h) suppressed
eactive oxygen species generation and p47
phox expression in
ononuclear cells and suppressed NF-kB and early growth
esponse-1 (20,21). Both the binding and expression of
arly growth response-1 and its protein were also sup-
ressed, whereas inhibitor kappa B, the intracellular inhib-
tor of NF-kB, was increased. Plasma concentrations of
ntracellular adhesion molecule-1, monocyte chemoattrac-
ant protein-1, matrix metalloproteinase-2 and -9, tissue
actor, and plasminogen activator inhibitor-1 also dropped
ignificantly following the insulin infusion during which
lasma glucose concentrations were maintained at a normo-
lycemic and constant level (20,21). We further showed in
bese subjects that vascular endothelial growth factor, a cyto-
ine that may contribute to neovascularization of the retina in
he pathogenesis of diabetic retinopathy and cause expansion of
xperimental MI extent in the rat (22) was also suppressed by
nsulin (23). Taken together, these findings support potent and
omprehensive anti-inflammatory and antioxidant effects for
nsulin. Onset is rapid, within 2 h, with the magnitude of this
bserved effect similar to that of 100 mg of hydrocortisone
iven intravenously.
uppressive Effect of
nsulin on Toll-Like Receptors (TLRs)
LRs are a class of pathogen-recognition receptors that
ind to bacterial, fungal, and viral products and induce
nflammation through the subsequent activation of proin-
ammatory transcription factors. TLR-4 is the specific
eceptor for the lipid-A moiety of endotoxin and, therefore,
ediates inflammatory changes induced by endotoxins (24).
LR-4 has also been shown to mediate diet-induced
besity, insulin resistance, and vascular inflammation
25,26). Thus, it is plausible that TLR-4 suppression by
nsulin is implicated in endotoxin-mediated inflammation, diet-induced obesity, insulin re-
istance, vascular inflammation,
nd atherogenesis. TLR-2 binds
o lipopeptides, glycolipids, and
eptide glycerol, which might play
role in ischemia-reperfusion–
nduced myocardial injury (27,28).
ur most recent studies in pa-
ients with type 2 diabetes have
hown that insulin infusion (2
/h) suppresses both TLR-2
nd -4 and PU1, the key tran-
cription factor involved in the
iosynthesis of TLRs (29).
nti-Inflammatory
nd Cardioprotective
ffects of Insulin in
xperimental Models
n a rat isolated heart preparation, the addition of insulin,
ven without glucose and potassium, at the time of reper-
usion following the ligation of the anterior descending
oronary artery reduced the size of the infarct by 45% (30).
his was attributed to an antiapoptotic action of insulin,
ediated via PI3 kinase, AkT, BAD, and NO synthase
hosphorylation (31). In a canine model of low-flow isch-
mia, insulin improved contractile function and myocardial
etabolic efficiency without alteration of adenosine triphos-
hate, phosphocreatine, and phosphate levels (32). In an in
ivo canine model of AMI, glucose and potassium infusion
nduced hyperglycemia and was shown to increase infarct
ize, but the administration of insulin with glucose and
otassium, or insulin alone, reduced infarct size and im-
roved left ventricular function (33). In total, the benefits of
nsulin were attributed to its antiapoptotic effect, suggesting
hat insulin is the main beneficial component of glucose,
nsulin, and potassium (GIK) infusion.
Another study in an in vivo rat model with AMI showed
hat induced hyperglycemia during ischemia was associated
ith increased infarct size (34). Hyperglycemia also neu-
ralized the benefits obtained by GIK infusion during
eperfusion, because the antiapoptotic effect of insulin,
ediated via a PI3 kinase-dependent pathway, was inhib-
ted. These findings underscore the need to avoid hypergly-
emia and maintain adequate insulin concentration during
nsulin infusion in ACS.
In other animal studies, insulin was shown to suppress
ndotoxin-induced proinflammatory transcription factors
nd genes regulated by them (35). These effects were shown
uring euglycemic conditions and, thus, are independent of
ny changes in glucose concentrations. A suppressive effect
f insulin on proinflammatory factors has also been dem-
nstrated in rats exposed to thermal injury (36). Insulin
reatment in a rat model of endotoxemia has been shown to
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
AMI  acute myocardial
infarction
CABG  coronary artery
bypass graft
CRP  C-reactive protein
GIK  glucose, insulin,
potassium
ICU  intensive care unit
NF-kB  nuclear factor-
kappa B
NO  nitric oxide
SAA  serum amyloid A
TLR  toll-like receptorecrease endotoxin-induced increase in poly(adenosine
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Insulin, Inflammation, and Atherosclerosis February 3, 2009:S14–20iphosphate–ribose) polymerase activity (37). In endotoxin-
reated human macrophage-1 cell line, insulin reduced the
ncrease in apoptosis, tissue necrosis factor-alpha, and
nterleukin-1-beta secretion. Lipopolysaccharide-treated
uman macrophage-1 cells were also shown to express less
xtracellular signal-related kinase-1 and -2, Jun kinase, p38
itogen-activated protein kinase, and NF-kB and to secrete
ess tissue necrosis factor-alpha and interleukin-8 following
nsulin pre-treatment (38). Clearly, insulin has a direct
nhibitory effect on endotoxin-induced inflammation.
nti-Inflammatory Effects of
nsulin in AMI, in the Intensive Care Unit
ICU), and in Coronary Artery Bypass Surgery
n patients with AMI, we found that an insulin infusion of
.5 U/h resulted in plasma insulin concentrations more than
wice as high as those at baseline, necessitating small
mounts of glucose to maintain normoglycemia (39). There
as an impressive 40% reduction in plasma CRP and serum
myloid A (SAA) concentrations at 24 h, which was
aintained after 48 h of insulin infusion (39). Insulin pre-
ented an increase in plasminogen activator inhibitor-1 con-
entrations induced by the thrombolytic agent reteplase and
revented the marked increase in p47
phox expression in mono-
uclear cells observed in patients who were given reteplase
lone. In addition, insulin infusion reduced promatrix
etalloproteinase-1 concentrations (39,40) and prevented a
eparin-induced increase in plasma free fatty acid concentra-
ions, which probably is secondary to heparin-induced lipolysis
n AMI. It did not lower basal elevated concentrations of free
atty acids in these patients (40).
The profound suppressive effects of insulin on CRP
oncentrations in patients with AMI shown by us have been
onfirmed by other groups (41). Insulin has also been shown
o induce a 40% reduction in CRP and SAA concentrations
n patients undergoing coronary artery bypass grafts
CABGs), in whom the increase in CRP and SAA is
30-fold than observed in AMI (42). In CABG patients,
he cessation of insulin infusion, with resultant increases in
lucose concentrations, also led to an increase in CRP and
AA within hours of insulin discontinuation. Furthermore,
RP-suppressive effects were observed only when insulin
as infused continuously, and not when injected as an
ntravenous bolus to maintain normoglycemia (43). This is
ost likely a function of the maintenance of a steady and
igher concentration of insulin when it is given as a
ontinuous infusion. Because elevated CRP concentrations
ppear to be related to the size of the infarct in patients with
MI, this effect may be considered cardioprotective. In our
tudy, insulin infusion reduced creatine kinase-myocardial
and in subjects with inferior MI, representing the largest
ingle subgroup (39). C-reactive protein may have an
mportant and independent role in the pathogenesis of
nfarct size because CRP injection in experimental MI
ncreased infarct size, but treatment with small molecules, ipecifically synthesized to bind CRP and block its action,
educed the infarct size (44). Clearly, a close relationship exists
mong glycemia, insulin, CRP, and SAA concentrations.
In patients with type 2 diabetes, insulin infusion to
ontrol glucose within 12 h of admission to the coronary
are unit for ACS reversed the platelet hyperaggregatory
ffects of hyperglycemia, an effect not seen with subcutane-
us insulin (45). In the ICU setting, insulin infusion
owered circulating levels of intracellular adhesion
olecule-1 and E-selectin and suppressed inducible NO
ynthase expression (46). In this study, increased plasma
O metabolite concentrations were predictive of mortality
n ICU patients. In another study, mitochondrial changes in
he inner membrane and cristae induced by oxidative stress
n ICU patients were also inhibited by insulin infusion,
hich helped to maintain euglycemia (47). Thus, further
vidence supports the protective effects of insulin on mito-
hondrial function and structure in patients with hypergly-
emia and ACS.
ntiatherosclerotic Effects of Insulin
everal epidemiological studies associated fasting hyperin-
ulinemia with an increase in cardiovascular morbidity and
ortality (48,49). However, no animal model or cellular
xperiments have convincingly demonstrated an increase in
ither atherosclerosis or key atherogenic factor(s) in vitro
nduced by pathophysiologically relevant insulin concentra-
ions. The consistent stimulatory effects of insulin on
mooth muscle cell proliferation with concomitant increase
n p38 mitogen-activated protein kinase have been shown
nly at concentrations of 10 to 100 nmol/l (equivalent to
,400 to 14,000 U/ml) (50). These concentrations are far
reater than in the grossly obese or in very insulin-resistant
opulations (fasting insulin of 25 to 50 U/ml). Moreover,
atients with insulin-secreting tumors with persistent hy-
erinsulinemia do not develop atherosclerosis (51).
In contrast, intensive insulin therapy, as demonstrated in
he DCCT (Diabetes Control and Complications Trial)
tudy, revealed a trend toward lower cardiovascular events.
his was confirmed several years later in the EDIC (Epi-
emiology of Diabetes Interventions and Complications)
tudy, an extension of DCCT (52). The EDIC study also
emonstrated a significantly lower progression of carotid
ntima-media thickness, an index of atherosclerosis (53).
More recently, studies in apolipoprotein E knockout mice
howed that the usual development of atherosclerosis is
educed by insulin administration (54). Furthermore, in
nsulin receptor substrate-2 knockout mice, interference
ith insulin signal transduction lead to atherogenesis (55).
aken together, these data support the antiatherogenic
ffects of insulin.
nsulin Infusion in AMI: Clinical Trials
he DIGAMI (Diabetes Mellitus Insulin-Glucose Infusion
n Acute Myocardial Infarction) 1 trial randomized 620
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February 3, 2009:S14–20 Insulin, Inflammation, and Atherosclerosisatients with type 2 diabetes and AMI to conventional
oronary unit management or insulin-glucose infusion for
24 h followed by multidose subcutaneous insulin for 3
onths (56). At discharge, blood glucose was significantly
ower in the insulin-infusion group than in the conventional
herapy group (148 mg/dl vs. 162 mg/dl, p  0.01). At 1
ear, hemoglobin A1c decreased significantly more in the
nsulin-infusion group (0.9% vs. 0.35%, p  0.05). The
-year mortality rate was 18.6% and 26.1% in the insulin-
nfusion and conventional therapy groups, respectively (p 
.027). More recently, however, 2 major trials of insulin-
lucose infusion in patients with ACS failed to demonstrate
mortality benefit (57,58). The DIGAMI 2 trial random-
zed 1,253 AMI patients with concomitant type 2 diabetes
o insulin-glucose infusion followed by insulin-based long-
erm glucose control, insulin-glucose infusion plus standard
lucose control, or routine metabolic management (57). All
groups had similar glycemic control throughout the study
nd, in particular, patients in the group receiving the
ombination of insulin-glucose infusion plus insulin-based
ong-term therapy did not reach their target goal (fasting
lucose 90 to 126 mg/dl). At 24 h, fasting glucose concen-
rations in the 2 insulin-glucose infusion groups were lower
han in the third group but still relatively high (164 mg/dl
s. 180 mg/dl). Because glucose is proinflammatory and
roapoptotic, as previously discussed, it is possible that
yperglycemia masked the benefits of insulin therapy. The
REATE-ECLA (Clinical Trial of Reviparin and Meta-
olic Modulation in Acute Myocardial Infarction Treat-
ent and Evaluation-Estudios Clinicos Latino America)
tudy randomized 20,201 patients with ST-segment eleva-
ion MI to high-dose GIK infusion plus usual care or usual
are alone (58). The GIK regimen, using 25 to 30 g of
lucose and 6 U/h of insulin resulted in hyperglycemia
mean glucose level: 187 mg/dl). When baseline glucose
evels in the control group were divided into tertiles, those in
he lowest tertile of glucose (126 mg/dl) had a mortality
ate of 6.6%, the middle tertile (126 to 144 mg/dl) of 8.5%,
nd the highest tertile (144 mg/dl) of 14%. In a reanalysis
f the CREATE-ECLA data regarding hyperglycemia-
elated mortality, we calculated that the GIK group in
REATE-ECLA should have demonstrated an excess of
ortality by 22% due to hyperglycemia induced by the GIK
nfusion (10% real mortality vs. 12.2% mortality as expected
rom the induced hyperglycemia) in GIK-treated patients
59). However, there was no increase in mortality in the
IK group when compared with the control group not
nfused with GIK. This led us to hypothesize that insulin in
he GIK infusion protected patients from the adverse effects
f hyperglycemia. This observation underlines the impor-
ance of maintaining euglycemia when considering insu-
in infusion treatment. Indeed, in a reanalysis of the
REATE-ECLA and the OASIS (Organization for the
ssessment of Strategies for Ischemic Syndromes)-6 trial
ata, it was found that an increase in the incidence of
ortality and heart failure was shown in patients infused gith GIK in the first 3 days after MI, a phase during which
yperglycemia occurred (60). On the other hand, mortality
nd heart failure were significantly lower in 3- and 30-day
eriods during which hyperglycemia induced by GIK had
esolved, and presumably, the cardioprotective effect of
nsulin was manifest. In these 2 studies, 40% of the subjects
ecame hyperglycemic (post-randomization blood glucose
144 mg/dl) for 24 h after admission, and of this group,
2% of the subjects had been randomized to the GIK arm.
he increase in mortality and heart failure in the first 3 days
bserved in the GIK group was attributed by the investiga-
ors to hyperglycemia, fluid overload, and hyperkalemia
nduced by GIK infusion (60). A post-randomization glu-
ose of144 mg/dl showed increased mortality at 3 days by
.5-fold compared with those with post-randomization
lucose of 126 mg/dl.
Another possible reason for the lack of benefit of GIK in
REATE-ECLA may have been the time of initiation of
IK after reperfusion therapy in the majority of patients. A
ecent study of GIK infusion at the time of reperfusion with
hrombolytic agents (mean of 3 h following chest pain)
emonstrated an impressive 88% reduction in major cardio-
ascular events at 1 year (61).
linical Trials With Insulin
herapy in ICU and CABG Patients
he first evidence on the outcomes of glycemic control with
ow-dose insulin infusions came from a study by Van den
erghe et al. in 2001 (62). In a prospective trial of 1,548
atients in a surgical ICU with a stay of 5 days, one-half
f patients were infused with insulin, rendering them
elatively euglycemic (fasting blood glucose: 110 mg/dl).
otal mortality was reduced by 48%, the incidence of
acteremia by 46%, renal failure requiring dialysis by 41%,
CU neuropathy by 44%, and the need for red blood cell
ransfusions by 50% when compared with control patients.
onversely, classical anti-inflammatory drugs such as the
lucocorticoids have been shown to increase mortality in ICU
atients (63) and, despite its anabolic effect, human growth
ormone therapy has not shown improved outcomes (64);
oth therapies also increase plasma glucose concentrations.
Van den Berghe et al. (62) also showed that outcomes
mproved with low-dose insulin infusions and the reduction
n CRP was more dependent on reduced plasma glucose
evels than on the dose of insulin administered. Van den
erghe et al. (62) focused on restoration and maintenance of
uglycemia; they did not examine the effects of maintaining
igh insulin concentrations, which would exert an indepen-
ent anti-inflammatory effect and benefit of insulin beyond
hat achieved through blood glucose normalization. Indeed,
n a subanalysis, they showed that plasma insulin concen-
rations were similar in the intensively treated and con-
rolled subjects (65).
In a prospective study designed to reduce and maintain
lucose 110 mg/dl in a medical ICU population requiring
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Insulin, Inflammation, and Atherosclerosis February 3, 2009:S14–20dmission for 3 days, Van den Berghe et al. (66) also
howed that insulin therapy decreased mortality by 18% and
educed the duration of mechanical ventilation and inci-
ence of renal injury compared with control patients (66).
ther benefits included reduced length of stay in the ICU
nd the hospital. This is consistent with Krinsley’s (67)
bservations in the medical ICU of a community teaching
ospital.
The role of lowering glucose concentrations in patients
ith diabetes undergoing CABG has been shown in a large
bservational study using historical controls (68). Improved
lycemia (reduction of glucose from 213 to 177 mg/dl) was
ssociated with a reduction in mortality from 5.3% to 2.5%
68). In a second, smaller randomized controlled trial,
aintaining good glycemic control with insulin led to
eductions in mortality, cardiac failure, and arrhythmias
69). A third, randomized trial in patients without diabetes
ndergoing CABG showed better myocardial function,
ecreased incidence of low cardiac output state, and a
eduction in myocardial injury following treatment with
IK (70).
In a recent trial of intensive insulin therapy to improve
lucose control in subjects with sepsis, controlling glucose to
110 mg/dl was not associated with an improvement in
ortality (71). Hypoglycemia, which occurred more fre-
uently in the intensively treated group, was an independent
isk factor for death in this study. Hypoglycemia on admis-
ion or during hospitalization has also been identified as
Figure 1 Rationale for the Use of Insulin in ACS
The anti-inflammatory, antiapoptotic, cardioprotective, and neuroprotective effects
latory, reactive oxygen species (ROS)-suppressive, antiplatelet, antithrombotic, and
dromes; cAMP  cyclic adenosine monophosphate; CRP  C-reactive protein; eNO
adhesion molecule; IKB  intracellular kappa B; MCP  monocyte chemoattractan
activator inhibitor; TF  tissue factor.eing associated with increased mortality in retrospective
nalyses of studies in ACS (72). It is possible that choosing
higher blood glucose target, between 110 and 130 mg/dl,
nd monitoring blood glucose more frequently reduces the
ncidence and duration of hypoglycemia while providing the
enefit of lowering glucose and insulin administration in
CS.
onclusions
apidly accumulating data demonstrate that the proinflamma-
ory and pro-oxidant actions of glucose, in addition to the
eactive oxygen species-suppressive and anti-inflammatory ac-
ions of insulin, likely play an important role in the pathogen-
sis and treatment of complications in patients with ACS
Fig. 1). Thus, maintenance of euglycemia with the help of
nsulin infusion may have a role in management of these
atients. Treatment of hyperglycemia with insulin results in
ual benefits—it lowers the proinflammatory effects of
lucose and induces the anti-inflammatory effects of insulin.
s observed in several studies of patients with AMI,
egimens that infuse fixed doses of insulin with high rates of
lucose infusion tend to be associated with hyperglycemia.
he induction of hyperglycemia may potentially neutralize
he benefits of insulin and thus these regimens should be
voided. This area clearly needs further definitive investiga-
ion. We are currently conducting a study to test whether
ow-dose insulin infusion that restores normoglycemia in
lin have been demonstrated both in humans and in animal models. The vasodi-
rinolytic effects have been demonstrated in humans. ACS  acute coronary syn-
ndothelial nitric oxide synthase; FFA  free fatty acid; ICAM  intracellular
ein; NFB  nuclear factor-kappa B; NO  nitric oxide; PAI  plasminogenof insu
profib
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rove clinical outcomes. We look forward to sharing these
esults with the cardiology community.
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